Table 1.
Metabolic syndrome components in patients with myelomeningocele (cont.)
| Authors | Design and setting/Participants | Assessment tools and protocols | Outcome measure | Results |
|---|---|---|---|---|
| Cross-sectional, outpatient (USA) 34 subjects with SB 16.3 ± 2.5 yo 52.9% male | DEXA BMI | Body fat | % Trunk fat SB group: 31.2 ± 9.6, (p ≤ .05 with control and SCI groups) SCI group: 30.9 ± 13.4 (p ≤ .05 with control group) Control group: 25.7 ± 12.8 | |
| Nelson et al. (2007)15 | 20 subjects with SCI 16.9 ± 3.0 55% male | % Body fat SB group: 40.0 ± 8.5 (p ≤ .05 with control and SCI groups) SCI group: 33.9 ± 12.5 (p ≤ .05 with control group) Control group: 28.0 ± 11.2 BMI z score SB group: 1.43±1.07 (p ≤ .05 with control and SCI groups) SCI group: 0.07 ± 2.29 (p ≤ .05 with control group) Control group: 0.73 ± 1.11 | ||
| 60 controls 16.2 ± 2.5 yo 45% male | Systolic blood pressure | Blood pressure | High blood pressure Nonobese SB group: 10%; Obese SB group: 29.2% Nonobese SCI group: 20%; Obese SCI group: 30% Nonobese control group: 12.2 %; Obese control group: 26.3 % | |
| Fasting blood glucose Fasting insulin HOMA-IR | Insulin-resistance | Impaired fasting blood glucose / elevated HOMA-IR Nonobese SB group: 0% / 0%; Obese SB group: 0% / 12.5% Nonobese SCI group: 0% / 0%; Obese SCI group: 0% / 60% Nonobese control group: 2.5% / 4.9%; Obese control group: 0% / 42.1% | ||
| HDL, TG, LDL, TC | Dyslipidemia Metabolic syndrome | Low HDL / High TG Nonobese SB group: 70% / 10%; Obese SB group: 75% / 33.3% Nonobese SCI group: 80% / 20%; Obese SCI group: 100% / 70% Nonobese control group: 56.1% / 24.4%; Obese control group: 84.2% / 36.8% |